Submit your email to push it up the queue
Pharmaceutics International, Inc. (PII), headquartered in the United States, is a leading player in the pharmaceutical contract development and manufacturing industry. Founded in 1997, the company has established a strong presence in key operational regions, including North America and Europe. PII specialises in the formulation and production of complex drug products, particularly in the areas of injectable and oral dosage forms. With a commitment to innovation, Pharmaceutics International offers unique services such as customised formulation development and comprehensive analytical testing. The company has achieved notable milestones, including successful partnerships with major pharmaceutical firms, which solidify its market position as a trusted provider in the industry. PII's dedication to quality and regulatory compliance sets it apart, making it a preferred choice for clients seeking reliable pharmaceutical solutions.
How does Pharmaceutics International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharmaceutics International, Inc.'s score of 82 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutics International, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Jabil Inc., which may influence its climate commitments and reporting practices. Pharmaceutics International, Inc. has not established any documented reduction targets or specific climate pledges. However, as part of its corporate family, it may align with the sustainability initiatives and targets set by Jabil Inc. This includes potential commitments to the Science Based Targets initiative (SBTi) and other climate-related frameworks, although specific details regarding these initiatives are not provided. As the company continues to develop its sustainability strategy, it is essential to monitor any future disclosures that may outline its carbon emissions and climate commitments more clearly.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 37,100,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 1,182,767,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 51,478,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmaceutics International, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.